Efficacy of systematic lymphadenectomy and adjuvant radiotherapy in node-positive endometrial cancer patients

Gynecologic Oncology

Volumn 101, Issue 2, 2006, Pages 200-208

  Mariani, Andrea ^a   Dowdy, Sean C ^a   Cliby, William A ^a   Haddock, Michael G ^a   Keeney, Gary L ^a   Lesnick, Timothy G ^a   Podratz, Karl C ^a  

^a MAYO CLINIC   (United States)

Author keywords

Adjuvant radiotherapy; Endometrial cancer; Lymph node dissection; Lymphadenectomy; Metastasis; Para aortic lymph nodes; Pelvic lymph nodes

Indexed keywords

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; DISEASE SEVERITY; ENDOMETRIUM CANCER; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MORBIDITY; MULTIMODALITY CANCER THERAPY; PARAAORTIC LYMPH NODE; PARAAORTIC LYMPHADENECTOMY; PELVIS LYMPH NODE; PELVIS LYMPHADENECTOMY; POSTOPERATIVE CARE; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK ASSESSMENT; THERAPY EFFECT;

AGED; COHORT STUDIES; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES;

EID: 33646392731     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.01.032     Document Type: Article

References (31)

1. Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A., et al. Cancer statistics, 2005. CA Cancer J. Clin. 55 (2005) 10-30
2. McMeekin D.S., and Tillmanns T. Endometrial cancer: treatment of nodal metastases. Curr. Treat Options Oncol. 4 (2003) 121-130
3. Creutzberg C.L., van Putten W.L., Koper P.C., Lybeert M.L., Jobsen J.J., Warlam-Rodenhuis C.C., et al. PORTEC Study Group. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomized trial. Lancet 355 (2000) 1404-1411
4. Wharton J.T., Jones III H.W., Day Jr. T.G., Rutledge F.N., and Fletcher G.H. Preirradiation celiotomy and extended field irradiation for invasive carcinoma of the cervix. Obstet. Gynecol. 49 (1977) 333-338
5. Corn B.W., Lanciano R.M., Greven K.M., Schultz D.J., Reisinger S.A., Stafford P.M., et al. Endometrial cancer with para-aortic adenopathy: patterns of failure and opportunities for cure. Int. J. Radiat. Oncol. Biol. Phys. 24 (1992) 223-227
6. Kilgore L.C., Partridge E.E., Alvarez R.D., Austin J.M., Shingleton H.M., Noojin III F., et al. Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling. Gynecol. Oncol. 56 (1995) 29-33
7. Onda T., Yoshikawa H., Mizutani K., Mishima M., Yokota H., Nagano H., et al. Treatment of node-positive endometrial cancer with complete node dissection, chemotherapy and radiation therapy. Br. J. Cancer 75 (1997) 1836-1841
8. Mariani A., Webb M.J., Galli L., and Podratz K.C. Potential therapeutic role of para-aortic lymphadenectomy in node-positive endometrial cancer. Gynecol. Oncol. 76 (2000) 348-356
9. Bristow R.E., Zahurak M.L., Alexander C.J., Zellars R.C., and Montz F.J. FIGO stage IIIC endometrial carcinoma: resection of macroscopic nodal disease and other determinants of survival. Int. J. Gynecol. Cancer 13 (2003) 664-672
10. Havrilesky L.J., Cragun J.M., Calingaert B., Synan I., Secord A.A., Soper J.T., et al. Resection of lymph node metastases influences survival in stage IIIC endometrial cancer. Gynecol. Oncol. 99 (2005 (Dec)) 689-695 [electronic publication 2005 Aug. 29]
11. Belinson J.L., Lee K.R., Badger G.J., Pretorius R.G., and Jarrell M.A. Clinical stage I adenocarcinoma of the endometrium: analysis of recurrences and the potential benefit of staging lymphadenectomy. Gynecol. Oncol. 44 (1992) 17-23
12. Rose P.G., Cha S.D., Tak W.K., Fitzgerald T., Reale F., and Hunter R.E. Radiation therapy for surgically proven para-aortic node metastasis in endometrial carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 24 (1992) 229-233
13. Creasman W.T., Odicino F., Maisonneuve P., Beller U., Benedet J.L., Heintz A.P., et al. Carcinoma of the corpus uteri. J. Epidemiol. Biostat. 6 (2001) 47-86
14. In: Scully R.E., Bonfiglio T.A., Kurman R.J., Silverberg S.G., and Wilkenson E.J. (Eds). Histological typing of female genital tract tumours. 2nd ed. (1994), Springer-Verlag, Berlin 13-18
15. American Society of Anesthesiology. New classification of physical status. Anesthesiology 24 (1963) 111
16. Pavy J.J., Denekamp J., Letschert J., Littbrand B., Mornex F., Bernier J., et al., EORTC Late Effects Working Group. Late effects toxicity scoring: the SOMA scale. Radiother. Oncol. 35 (1995) 11-15
17. Cady B. Lymph node metastases: indicators, but not governors of survival. Arch. Surg. 119 (1984) 1067-1072
18. Kinney W.K., Hodge D.O., Egorshin E.V., Ballard D.J., and Podratz K.C. Surgical treatment of patients with stages IB and IIA carcinoma of the cervix and palpably positive pelvic lymph nodes. Gynecol. Oncol. 57 (1995) 145-149
19. Kupets R., Thomas G.M., and Covens A. Is there a role for pelvic lymph node debulking in advanced cervical cancer?. Gynecol. Oncol. 87 (2002) 163-170
20. Rose P.G. Chemoradiotherapy for cervical cancer. Eur. J. Cancer 38 (2002) 270-278
21. Bolis G., van Zaiten-Przybysz I., Scarfone G., Zanaboni F., Scarabelli C., Tateo S., et al. Determinants of response to a cisplatin-based regimen as neoadjuvant chemotherapy in stage IB-IIB invasive cervical cancer. Gynecol. Oncol. 63 (1996) 62-65
22. Mariani A., Webb M.J., Keeney G.L., Aletti G., and Podratz K.C. Predictors of lymphatic failure in endometrial cancer. Gynecol. Oncol. 84 (2002) 437-442
23. Mariani A., Keeney G.L., Aletti G., Webb M.J., Haddock M.G., and Podratz K.C. Endometrial carcinoma: paraaortic dissemination. Gynecol. Oncol. 92 (2004) 833-838
24. Sood B.M., Timmins P.F., Gorla G.R., Garg M., Anderson P.S., Vikram B., et al. Concomitant cisplatin and extended field radiation therapy in patients with cervical and endometrial cancer. Int. J. Gynecol. Cancer 12 (2002) 459-464
25. Soper J.T., Reisinger S.A., Ashbury R., Jones E., and Clarke-Pearson D.L. Feasibility study of concurrent weekly cisplatin and whole abdominopelvic irradiation followed by doxorubicin/cisplatin chemotherapy for advanced stage endometrial carcinoma: a Gynecologic Oncology Group trial. Gynecol. Oncol. 95 (2004) 95-100
26. Greven K., Winter K., Underhill K., Fontenesci J., Cooper J., and Burke T. Radiation Therapy Oncology Group. Preliminary analysis of RTOG 9708: adjuvant postoperative radiotherapy combined with cisplatin/paclitaxel chemotherapy after surgery for patients with high-risk endometrial cancer. Int. J. Radiat. Oncol. Biol. Phys. 59 (2004) 168-173
27. Frigerio L., Mangili G., Aletti G., Carnelli M., Garavaglia E., Beatrice S., et al. Concomitant radiotherapy and paclitaxel for high-risk endometrial cancer: first feasibility study. Gynecol. Oncol. 81 (2001) 53-57
28. Creutzberg C.L., van Putten W.L., Koper P.C., Lybeert M.L., Jobsen J.J., Warlam-Rodenhuis C.C., et al., PORTEC Study Group. Survival after relapse in patients with endometrial cancer: results from a randomized trial. Gynecol. Oncol. 89 (2003) 201-209
29. Cliby W.A., Clarke-Pearson D.L., Dodge R., Kohler M.F., Rodriguez G., Olt G.J., et al. Acute morbidity and mortality associated with selective pelvic and paraaortic lymphadenectomy in the surgical staging of endometrial adenocarcinoma. J. Gynecol. Tech. 1 (1995) 19-26
30. Aoki Y., Kase H., Watanabe M., Sato T., Kurata H., and Tanaka K. Stage III endometrial cancer: analysis of prognostic factors and failure patterns after adjuvant chemotherapy. Gynecol. Oncol. 83 (2001) 1-5
31. Fleming G.F., Brunetto V.L., Cella D., Look K.Y., Reid G.C., Munkarah A.R., et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol. 22 (2004) 2159-2166